Use of medicines for covid-19 treatment in patients with loss of kidney function: a narrative review.
Lucas Lobato Acatauassu NunesTácio de Mendonça LimaPublished in: Jornal brasileiro de nefrologia : 'orgao oficial de Sociedades Brasileira e Latino-Americana de Nefrologia (2021)
Covid-19 has been identified as the cause of acute respiratory disease with interstitial and alveolar pneumonia, but it can affect several organs, such as kidneys, heart, blood, nervous system and digestive tract. The disease-causing agent (Sars-CoV-2) has a binding structure to the angiotensin-converting enzyme 2 (ACE2) receptor, enabling entry into cells that express ACE2, such as the pulmonary alveolar epithelial cells. However, studies also indicate the possibility of damage to renal cells, since these cells express high levels of ACE2. Currently, there is no evidence to indicate a specific treatment for covid-19. Several drugs have been used, and some of them may have their excretion process altered in patients with abnormal kidney function. To date, there are no studies that assist health professionals in adjusting the dose of these drugs. Thus, this study aims to review and discuss the topic, taking into account factors associated with kidney injury in covid-19, as well as pharmacokinetic aspects and dose recommendations of the main drugs used for covid-19.
Keyphrases
- sars cov
- coronavirus disease
- angiotensin converting enzyme
- induced apoptosis
- angiotensin ii
- respiratory syndrome coronavirus
- cell cycle arrest
- oxidative stress
- endoplasmic reticulum stress
- pulmonary hypertension
- liver failure
- signaling pathway
- cell death
- intensive care unit
- cell proliferation
- respiratory failure
- hepatitis b virus
- clinical practice
- pi k akt
- acute respiratory distress syndrome
- mechanical ventilation